Luveltamab tazevibulin
As of the edition of 20 October 2026, Luveltamab tazevibulin is an antibody drug conjugate: stopped in 2025; acts on FOLR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Antibody drug conjugate
- Registered trials
- 6, 4 stopped early
- Disease areas
- Cancer; Hormones; Pregnancy and women's health; Urinary and reproductive; Blood and lymph; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Luveltamab tazevibulin.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FOLR1 | Folate receptor alpha | P15328 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 3 | 1 | 0 | 2 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sutro Biopharma | Lead sponsor of trials | 2019 to now |
| Tasly Pharmaceutical | Lead sponsor of trials | 2023 to now |